Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering ...

A team at Huntsman Cancer Institute at the University of Utah (the U) has uncovered a previously unrecognized molecular ...

MIT engineers have developed a new way to amplify the T-cell response to mRNA vaccines—an advance that could lead to much ...

An epigenetic mechanism by which tumors manage to hide from the body's immune defenses has just been described by an ...

Researchers have uncovered an unexpected weakness in pancreatic cancer involving damaged mitochondria and a powerful ...

Aspirin reduces the risk of colon cancer recurrence after surgery, but only in patients with a specific genetic marker ...

Tumors do not communicate only with immune cells, blood vessels, and stromal tissue. A growing body of evidence suggests that cancer can also co-opt the nervous system, reshaping the tumor ...

Targeting the WNT signaling pathway represents a promising strategy for cancer therapy. The field has evolved to include numerous inhibitors currently under preclinical and clinical investigation.

New findings suggest that melanoma does not behave uniformly across the lifespan, with immune defenses and tumor activity ...

Structural insight into KRAS conformational cycling exposed temporary binding opportunities, overturning the “undruggable” ...